Display options
Cite
Sutani S, Yorozu A, Toya K, et al. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of . J Contemp Brachytherapy. 2019;11(3):201-206doi: 10.5114/jcb.2019.86163.
Sutani, S., Yorozu, A., Toya, K., Nishiyama, T., Ozu, C., Yagi, Y., Nakamura, K., & Saito, S. (2019). Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of . Journal of contemporary brachytherapy, 11(3), 201-206. https://doi.org/10.5114/jcb.2019.86163
Sutani, Shinya, et al. "Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of ." Journal of contemporary brachytherapy vol. 11,3 (2019): 201-206. doi: https://doi.org/10.5114/jcb.2019.86163
Sutani S, Yorozu A, Toya K, Nishiyama T, Ozu C, Yagi Y, Nakamura K, Saito S. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of . J Contemp Brachytherapy. 2019 Jun;11(3):201-206. doi: 10.5114/jcb.2019.86163. Epub 2019 Jun 28. PMID: 31435426; PMCID: PMC6701380.
Copy Download .nbib Format: NLM
Share it on

J Contemp Brachytherapy. 2019 Jun;11(3):201-206. doi: 10.5114/jcb.2019.86163. Epub 2019 Jun 28.

Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of .

Journal of contemporary brachytherapy

Shinya Sutani, Atsunori Yorozu, Kazuhito Toya, Toru Nishiyama, Choichiro Ozu, Yasuto Yagi, Ken Nakamura, Shiro Saito

Affiliations

  1. Department of Radiation Oncology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  2. Department of Radiation Oncology, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  3. Department of Urology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.

PMID: 31435426 PMCID: PMC6701380 DOI: 10.5114/jcb.2019.86163

Abstract

PURPOSE: To analyze outcomes following whole-gland salvage treatments applied to patients with pathology-proven, locally recurrent prostate cancer following primary definitive radiotherapy.

MATERIAL AND METHODS: Eighteen consecutive patients who received whole-gland salvage treatments at our institution were retrospectively reviewed. All patients underwent transperineal template-guided mapping biopsy (TTMB) using the standard iodine-125 (

RESULTS: The median follow-up times were 71 and 11 months for the BT and RARP groups, respectively. In the BT group, the median dose to 90% of the prostate was 131 Gy. The median time to biochemical failure was 47 months, and the biochemical relapse-free survival (BRFS) rates were 56% (95% confidence interval [CI]: 33-94%) and 46% (95% CI: 25-88%) at 3 years and 5 years, respectively. Four patients (33%) developed grade 2 genitourinary (GU) toxicity, and two (17%) developed grade 3 GU toxicity. No patients developed grade ≥ 2 gastrointestinal (GI) toxicity. In the RARP group, three out of six patients (50%) had PSA failure, and four patients (67%) developed grade 2 GU toxicity. No patients developed grade 3 GU toxicity or grade ≥ 2 GI toxicity. On pre-salvage magnetic resonance imaging (MRI), no patients were suspected of having T3 or higher stage lesions. However, three patients (50%) had pT3a and two patients (33%) had pT3b (i.e., seminal vesicle invasion) stage lesions.

CONCLUSIONS: Whole-gland salvage BT is an effective treatment with an acceptable toxicity profile. The pathology findings from RARP imply that there is a room for improvement in diagnoses made by MRI in the pre-salvage setting.

Keywords: brachytherapy; prostate cancer; prostatectomy; salvage therapy

References

  1. Urology. 1999 Nov;54(5):880-3 - PubMed
  2. Cancer. 2007 Oct 1;110(7):1485-92 - PubMed
  3. BJU Int. 2009 Sep;104(5):600-4 - PubMed
  4. Brachytherapy. 2010 Apr-Jun;9(2):119-25 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44 - PubMed
  6. Eur Urol. 2011 Aug;60(2):205-10 - PubMed
  7. BJU Int. 2013 Jun;111(8):E342-7 - PubMed
  8. Brachytherapy. 2014 Jan-Feb;13(1):53-8 - PubMed
  9. Brachytherapy. 2015 Mar-Apr;14(2):111-7 - PubMed
  10. Brachytherapy. 2015 May-Jun;14(3):342-9 - PubMed
  11. Brachytherapy. 2016 Jan-Feb;15(1):85-93 - PubMed
  12. Semin Radiat Oncol. 2017 Jan;27(1):67-78 - PubMed
  13. Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285 - PubMed
  14. Eur Urol. 2018 Apr;73(4):488-490 - PubMed
  15. JAMA Oncol. 2018 Jun 14;4(6):e180039 - PubMed
  16. J Contemp Brachytherapy. 2018 Apr;10(2):169-173 - PubMed
  17. Int J Clin Oncol. 2018 Dec;23(6):1148-1159 - PubMed
  18. Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343 - PubMed
  19. Urology. 1999 Jan;53(1):2-10 - PubMed

Publication Types